公开(公告)号：US09044401B2

公开(公告)日：2015-06-02

申请号：US13698619

申请日：2011-06-03

申请人： Sang-Geun Park ,  Chang-Kyoo Lee ,  Tae-Won Lee

发明人： Sang-Geun Park ,  Chang-Kyoo Lee ,  Tae-Won Lee

IPC分类号： A61K31/593 ,  A61K9/20 ,  A61K31/663 ,  A61K45/06

CPC分类号： A61K9/20 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/593 ,  A61K31/663 ,  A61K45/06 ,  A61K2300/00

摘要： Provided is a composition for preventing or treating osteoporosis. The composition contains an ibandronic acid, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and vitamin D. The composition has uniform medicinal effects by minimizing the differences in physical properties between ibandronic acid, or the pharmaceutically acceptable salt thereof, or the hydrate thereof, and vitamin D.

摘要翻译： 提供了用于预防或治疗骨质疏松症的组合物。 该组合物含有伊班膦酸或其药学上可接受的盐，或其水合物和维生素D.该组合物具有均匀的药用作用，通过使伊班膦酸或其药学上可接受的盐或水合物的物理性质的差异最小化 和维生素D.

公开(公告)号：US20130096091A1

公开(公告)日：2013-04-18

申请号：US13698619

申请日：2011-06-03

申请人： Sang-Geun Park ,  Chang-Kyoo Lee ,  Tae-Won Lee

发明人： Sang-Geun Park ,  Chang-Kyoo Lee ,  Tae-Won Lee

IPC分类号： A61K9/20

CPC分类号： A61K9/20 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/593 ,  A61K31/663 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a composition for preventing or treating osteoporosis which comprises an ibandronic acid, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and vitamin D. The present invention relates to a composition for preventing or treating osteoporosis which has uniform medicinal effects by minimizing the differences in physical properties between ibandronic acid, or the pharmaceutically acceptable salt thereof, or the hydrate thereof, and vitamin D.

摘要翻译： 本发明涉及一种用于预防或治疗骨质疏松症的组合物，其包含伊班膦酸或其药学上可接受的盐，或其水合物和维生素D.本发明涉及用于预防或治疗骨质疏松症的组合物，其具有均匀的药物 通过最小化伊班膦酸或其药学上可接受的盐，或其水合物和维生素D之间的物理性质的差异的作用。

公开(公告)号：US20130095180A1

公开(公告)日：2013-04-18

申请号：US13805028

申请日：2011-07-05

申请人： Chang-Kyoo Lee ,  Sang-Geun Park

发明人： Chang-Kyoo Lee ,  Sang-Geun Park

IPC分类号： A61K31/522 ,  A61K31/4985 ,  A61K31/138

CPC分类号： A61K31/522 ,  A61K9/209 ,  A61K31/138 ,  A61K31/4985 ,  A61K31/519

摘要： The present invention relates to a time-delayed sustained release pharmaceutical composition for oral administration, which comprises an immediate release phase and a prolonged sustained release phase, wherein said immediate release phase and prolonged sustained release phase respectively comprise Dapoxetine therein as an active ingredient. The pharmaceutical composition of the present invention comprises Dapoxetine, which is an agent for treating premature ejaculation, in both the immediate release phase and the prolonged sustained release phase thereof, to thereby immediately exhibit the effectiveness of the pharmaceutical composition of the present invention in order to enable a patient to achieve sexual satisfaction during the early stage of administration, as well as to reduce side effects by means of the time-delayed sustained release of the prolonged sustained release phase during the early stage of administration and enable a continuous in vivo absorption of Dapoxetines, to thereby lengthen the duration of the effectiveness of the pharmaceutical composition of the present invention. Further, agents for treating erectile dysfunction, such as sildenafil, tadalifil or the like can be added to the immediate release phase so as to allow for a coincidence of the durations of the effectiveness of a premature ejaculation treatment agent and erectile dysfunction treatment agents, even though a half-life difference exists between the two types of treatment agents, thus maximizing patient satisfaction.

摘要翻译： 本发明涉及用于口服给药的时间延迟缓释药物组合物，其包括立即释放期和延长的持续释放期，其中所述立即释放期和延长的持续释放期分别包含其中的他帕西汀作为活性成分。 本发明的药物组合物在立即释放阶段和延长的持续释放阶段中包含作为治疗早泄的药剂达波西汀，从而立即显示本发明的药物组合物的有效性，以便 使患者能够在给药的早期阶段达到性满意度，并且通过在给药的早期阶段延长的持续释放期延缓持续释放来减少副作用，并且能够连续体内吸收 达波西汀，从而延长本发明的药物组合物的有效性的持续时间。 此外，用于治疗勃起功能障碍的药物，例如西地那非，他达拉芬等可以加入到立即释放阶段，以便使早泄治疗剂和勃起功能障碍治疗剂的效力持续时间一致，甚至 尽管两种类型的治疗剂之间存在半衰期差异，从而使患者满意度最大化。